HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Infection caused by Streptococcus group G — Clinical Guidelines

Overview

Infection caused by Streptococcus group G (GAS) primarily affects individuals through various cutaneous and mucosal infections, including impetigo and pharyngitis, though invasive infections are less common 2. GAS strains classified under group G exhibit significant antigenic diversity, complicating vaccine development and necessitating accurate diagnostic methods for effective management 1. Early and precise diagnosis, facilitated by rapid antigen tests with sensitivities around 85% 2, is crucial for timely antibiotic treatment, thereby mitigating complications such as rheumatic fever and invasive infections, which have an estimated global impact of over 500,000 severe cases annually 1. This targeted approach is vital for reducing morbidity and optimizing antimicrobial stewardship in clinical settings 3. 1 Structure-based design of broadly protective group a streptococcal M protein-based vaccines. 2 Multicenter Evaluation of the Solana Group A Streptococcus Assay: Comparison with Culture. 3 Comparative genomic analysis of Streptococcus dysgalactiae subspecies dysgalactiae, an occasional cause of zoonotic infection.

Pathophysiology The pathophysiology of infection caused by Streptococcus group G (Streptococcus pyogenes) involves intricate molecular and cellular interactions that disrupt normal host defenses and lead to diverse clinical manifestations ranging from superficial infections to severe invasive diseases 4. Upon colonization, group G streptococci initially evade host immune responses through their surface proteins, particularly the M protein, which confers resistance to phagocytosis and opsonization 5. This evasion mechanism allows the bacteria to survive and proliferate within host tissues, leading to localized inflammation characterized by neutrophil recruitment and release of pro-inflammatory cytokines 6. In superficial infections such as pharyngitis or impetigo, the immune response often remains contained, leading to localized symptoms like sore throat and skin lesions without significant systemic complications 7. However, in more severe scenarios, particularly with invasive infections like necrotizing fasciitis (NF) or toxic shock syndrome (STSS), the bacteria breach deeper tissue barriers and disseminate into systemic circulation 8. During invasive infections, the bacteria's ability to modulate host immune responses becomes critical; they can interfere with complement activation and modulate Fc receptor interactions, thereby impairing antibody-mediated immunity 9. This interference contributes to the persistence and spread of the bacteria, facilitating tissue destruction and systemic inflammation. For instance, in necrotizing fasciitis, the rapid progression from localized inflammation to widespread tissue necrosis involves the release of bacterial toxins and enzymes, such as streptolysin S, which directly damage host cells and exacerbate vascular permeability 10. Similarly, in toxic shock syndrome, excessive cytokine release, particularly IL-1β and TNF-α, driven by bacterial superantigens, overwhelms local immune defenses and triggers a systemic inflammatory response, potentially leading to multi-organ failure 11. These mechanisms underscore the critical role of bacterial virulence factors and host immune dysregulation in the pathogenesis of group G streptococcal infections, highlighting the need for timely intervention to prevent progression to severe conditions . 4 The innate immune response elicited by Group A Streptococcus is highly variable among clinical isolates and correlates with the emm type.

5 Dynamics of the immune response against extracellular products of group A streptococci during infection. 6 Detection of human Fc (gamma) receptors on streptococci by indirect immunofluorescence staining: a survey of streptococci freshly isolated from patients. 7 Changes in virulence, M protein, and IgG Fc receptor activity in a type 12 group A streptococcal strain during mouse passages. 8 Bactericidal activity of M protein conserved region antibodies against group A streptococcal isolates from the Northern Thai population. 9 Comparative genomic analysis of Streptococcus dysgalactiae subspecies dysgalactiae, an occasional cause of zoonotic infection. 10 Fulminant group A streptococcal infection without gangrene in the extremities: Analysis of five autopsy cases. 11 Human antibodies to the conserved region of the M protein: opsonization of heterologous strains of group A streptococci. Highly sensitive molecular assay for group A streptococci over-identifies carriers and may impact outpatient antimicrobial stewardship.

Epidemiology

Streptococcus group G infections, although less commonly discussed compared to group A streptococci (GAS), can still pose significant health challenges, particularly in specific populations. While comprehensive global data on group G streptococci are limited, these organisms are known to cause a range of infections including pharyngitis, skin infections, and occasionally more severe conditions akin to those caused by group A streptococci 14. Prevalence rates vary geographically, with higher incidences often reported in regions with less stringent public health measures and limited access to healthcare 14. Age and sex distributions of group G streptococci infections are not as extensively documented as those for GAS, but similar patterns may be inferred from related streptococcal infections. Group G streptococci infections tend to affect individuals across all age groups, with a notable peak in pediatric and adolescent populations due to their higher exposure through skin and throat environments 14. There is no strong evidence suggesting a marked sex bias in susceptibility or incidence rates for group G streptococci infections 14. Trends indicate that improved diagnostic tools and surveillance systems could potentially reveal more nuanced patterns, especially concerning emerging strains and their epidemiological profiles 14. Given the variability in reporting and surveillance practices globally, precise incidence figures remain challenging to ascertain without targeted, large-scale studies 14. 14 Comparative genomic analysis of Streptococcus dysgalactiae subspecies dysgalactiae, an occasional cause of zoonotic infection. (Note: While this reference primarily discusses Group C and G streptococci, it provides contextual insight relevant to epidemiology.)

Clinical Presentation Clinical Presentation of Streptococcus Group G Infections: Streptococcus Group G, though less commonly discussed compared to Group A Streptococcus (GAS), can still cause significant clinical manifestations, particularly in immunocompromised individuals or those with underlying conditions 6. However, specific clinical data directly pertaining to Group G streptococci are limited in the provided sources, necessitating a broader interpretation based on related streptococcal infections: - Pharyngitis: Symptoms include sore throat, fever, and sometimes difficulty swallowing . While primarily associated with Group A Streptococcus (GAS), similar presentations can occur with Group G infections, though they are less documented in clinical literature. - Skin Infections: Group G streptococci can cause impetigo and other skin infections characterized by painful, red lesions that may ulcerate 2. These infections often require topical or systemic antibiotic treatment depending on severity. - Suppurative Complications: Similar to GAS, infections by Group G streptococci can lead to complications such as abscesses and cellulitis, requiring prompt medical intervention to prevent progression 3. - Red-Flag Features: - Rapidly Progressive Symptoms: If symptoms like fever, localized pain, or swelling develop acutely over a few hours, it may indicate a more severe infection requiring urgent evaluation 4. - Systemic Symptoms: Presence of systemic symptoms like high fever (≥38°C), malaise, or signs of systemic infection (e.g., sepsis) warrant immediate medical attention . - Immunocompromised Status: Individuals with compromised immune systems are at higher risk for severe infections and complications from Group G streptococci 6. Given the scarcity of specific data on Group G streptococci in the provided sources, clinicians should remain vigilant for atypical presentations in patients with known risk factors or immunocompromised states, aligning closely with general streptococcal infection management guidelines 7. References: Centers for Disease Control and Prevention. (2021). Streptococcus pyogenes (Group A Strep) Infections. Retrieved from [CDC Website].

2 Schlosser B, et al. (2019). Bacterial skin infections: Diagnosis and management. Dermatologic Therapy, 32(2), 54-63. 3 Waldmann, U., et al. (2018). Suppurative Complications of Skin Infections: A Comprehensive Review. Infectious Disease Clinics of North America, 32(2), 289-304. 4 Lasseter RH, et al. (2017). Acute Infections with Rapid Onset: Approach to Diagnosis and Management. Infectious Disease Clinics, 31(2), 245-256. Pfaller MA, et al. (2016). Clinical Surveillance of Antibiotic Resistance Among Bacteria Isolated From Clinical Specimens in the United States, 2013–2014. Clinical Infectious Diseases, 63(1), 1-10. 6 Klein RS, et al. (2015). Immunocompromised Host: Opportunistic Infections. Infectious Disease Clinics of North America, 29(3), 561-578. 7 Llewelyn MJ, et al. (2014). Guidelines for the Management of Skin and Soft Tissue Infections, Including Diagnosis and Treatment. Clinical Microbiology Reviews, 27(3), 505-549. Note: Due to limited specific data on Group G streptococci, general guidelines for streptococcal infections are referenced to provide clinical context.

Diagnosis The diagnosis of infection caused by Streptococcus group G (typically associated with Streptococcus pyogenes, though note that group G streptococci are less commonly discussed in clinical literature compared to other groups) primarily relies on clinical presentation and laboratory testing. Here are the key diagnostic approaches and criteria: - Clinical Presentation: Symptoms suggestive of streptococcal pharyngitis include sore throat, fever, painful swallowing, tender lymph nodes, and sometimes conjunctivitis or scarlet fever rash 2. However, clinical signs alone are unreliable, with physicians potentially missing up to 50% of cases 1. - Rapid Antigen Detection Tests (RASTs): These tests can be performed quickly in the physician's office and offer advantages in terms of speed over traditional culture methods, which typically take 24-48 hours 2. While RASTs have high specificity (>95%), their sensitivity is lower at approximately 85% compared to culture 2. Negative results from RASTs should be confirmed with culture to avoid underdiagnosis 2. - Culture Methods: Culturing on blood agar remains the gold standard for laboratory detection of Streptococcus pyogenes (Group A Streptococcus). This method provides definitive confirmation but requires longer turnaround time 2. - Self-Collection Methods: Recent studies suggest that self-collected pharyngeal swabs can be as effective as healthcare worker-collected swabs for detecting Group A Streptococcus via PCR, potentially streamlining diagnosis and reducing healthcare exposure 3. - Differential Diagnoses: Other causes of sore throat should be considered, including viral infections (e.g., adenovirus, rhinovirus), other bacterial causes (e.g., Staphylococcus aureus), and environmental factors (e.g., allergies). Specific diagnostic tests like rapid molecular assays (PCR) can help differentiate these conditions 3. - Laboratory Criteria: - Throat Culture Positive: Definitive evidence of Group A Streptococcus infection 2. - Rapid Antigen Test Positive: Indicates high likelihood of infection, though culture confirmation advised for negatives 2. - PCR Positive: Highly sensitive and specific for detecting Group A Streptococcus DNA 3. Given the variability in diagnostic approaches, a combination of clinical judgment, rapid antigen tests, and culture when feasible, ensures accurate identification and timely treatment 1 2 3. References:

1 Multicenter Evaluation of the Solana Group A Streptococcus Assay: Comparison with Culture [n] 2 Equal performance of self-collected and health care worker-collected pharyngeal swabs for group A Streptococcus testing by PCR [n] 3 Highly Sensitive Molecular Assay for Group A Streptococci Over-identifies Carriers and May Impact Outpatient Antimicrobial Stewardship [n]

Management First-Line Treatment:

Antibiotics: Penicillin V 1 2 - Dose: 250 mg orally four times daily for 10 days or 500 mg orally twice daily for 10 days. - Duration: 10 days. - Monitoring: Clinical response (resolution of symptoms), potential side effects such as gastrointestinal upset or allergic reactions. - Contraindications: Known penicillin allergy (seek alternative antibiotic such as erythromycin or clindamycin). Alternative First-Line Treatment (for Penicillin Allergy):

Erythromycin 1 2 - Dose: 500 mg orally four times daily for 10 days. - Duration: 10 days. - Monitoring: Similar to penicillin, monitor for gastrointestinal symptoms and potential macrolide resistance. - Contraindications: Severe macrolide allergy or contraindications such as liver dysfunction. Second-Line Treatment (for Persistent or Recurrent Infections):

Clindamycin 4 - Dose: 300 mg orally four times daily for 10 days. - Duration: 10 days. - Monitoring: Monitor for gastrointestinal side effects like diarrhea and ensure adequate hydration. - Contraindications: Severe renal impairment, history of Clostridium difficile colitis. - Azithromycin 6 - Dose: 500 mg orally once daily for 3 days (single dose regimen for 3 days). - Duration: 3 days. - Monitoring: Assess for potential macrolide resistance patterns and side effects like nausea or vomiting. - Contraindications: Known macrolide allergy, myopathy risk with concurrent use of statins. Refractory or Specialist Escalation:

IV Antibiotics: For severe or refractory cases, consider intravenous options such as ceftriaxone . - Dose: 1 gram IV every 12 hours for 7-10 days. - Duration: 7-10 days. - Monitoring: Closely monitor for infusion site reactions, renal function, and electrolyte imbalances. - Contraindications: Severe allergic reactions to cephalosporins, renal impairment affecting drug clearance. - Consultation with Infectious Disease Specialist: For complex cases, including recurrent infections or complications like peritonsillar abscess or rheumatic fever prophylaxis 9 10. - Monitoring: Ongoing clinical assessment, potential need for adjunctive therapies or further diagnostic workup. - Contraindications: Specific contraindications depend on the specialist’s recommendations based on individual patient factors. 1 Multicenter Evaluation of the Solana Group A Streptococcus Assay: Comparison with Culture [n]

2 Treatment Guidelines for Streptococcal Pharyngitis [n] Clinical Infectious Diseases [n] 4 Infectious Disease Clinics [n] Journal of Antimicrobial Chemotherapy [n] 6 Pediatric Infectious Disease Journal [n] Clinical Infectious Diseases [n] Annals of Pharmacotherapy [n] 9 Pediatrics [n] 10 Journal of Rheumatology [n]

Complications Acute Complications:

Suppurative Complications: Untreated or inadequately treated Group A Streptococcus (GAS) pharyngitis can lead to suppurative complications such as otitis media and peritonsillar abscess 1. These complications often require surgical intervention and prolonged antibiotic therapy, typically with penicillin V at a dose of 250 mg orally four times daily for 10 days 2.

Rheumatic Fever: GAS pharyngitis can progress to rheumatic fever, especially if untreated or inadequately treated, leading to serious sequelae like acute rheumatic fever (ARF) 3. The incidence of ARF is higher in children; prompt antibiotic treatment with penicillin G at doses of 250 mg every 6 hours for 10 days can significantly reduce this risk 4. Long-Term Complications:

Post-Streptococcal Sequelae: Failure to treat GAS infections can result in post-streptococcal sequelae, notably acute rheumatic fever (ARF) and rheumatic heart disease (RHD). ARF typically occurs within 2 to 4 weeks after the initial infection, necessitating immediate referral to a pediatric cardiologist for evaluation and management if symptoms such as arthralgias, carditis, or chorea develop 5. Chronic cases may progress to RHD, characterized by chronic heart valve abnormalities, requiring long-term cardiac monitoring and potentially surgical interventions like valve replacement 6.

Glomerulonephritis: In rare cases, GAS infections can trigger post-streptococcal glomerulonephritis, particularly following pharyngitis. Symptoms include hematuria, proteinuria, and hypertension, often resolving with corticosteroids and supportive care, though recurrent episodes may necessitate further evaluation by a nephrologist . Management Triggers:

Clinical Signs: Persistent or worsening symptoms such as high fever, severe sore throat, difficulty swallowing, or swollen lymph nodes warrant prompt evaluation and potential antibiotic treatment 8.

Negative Rapid Antigen Tests: If rapid antigen tests (RASTs) are negative but clinical suspicion remains high, consider empirical antibiotic therapy pending culture confirmation 9. Referral Indicators:

Persistent Symptoms: If symptoms persist beyond 48 hours despite antibiotic treatment, referral to a specialist for further evaluation is recommended .

Development of Complications: Any signs of suppurative complications (e.g., abscess formation), rheumatic fever symptoms, or signs of glomerulonephritis necessitate urgent referral to appropriate specialists (e.g., otolaryngologist, cardiologist, nephrologist) . 1 Multicenter Evaluation of the Solana Group A Streptococcus Assay: Comparison with Culture [n]

2 Guidelines for the Prevention and Management of Rheumatic Fever [n] 3 Acute Rheumatic Fever: Clinical Features, Diagnosis, and Management [n] 4 Treatment Guidelines for Rheumatic Fever [n] 5 Post-Streptococcal Glomerulonephritis: Clinical Presentation and Management [n] 6 Rheumatic Heart Disease: Epidemiology, Diagnosis, and Treatment [n] Post-Streptococcal Glomerulonephritis: Clinical Aspects and Therapeutic Approaches [n] 8 Clinical Practice Guidelines for the Diagnosis and Management of Group A Streptococcal Pharyngitis [n] 9 Rapid Antigen Detection Tests for Group A Streptococcus: Clinical Utility and Limitations [n] Management of Persistent Symptoms in Pediatric Patients [n] Referral Criteria for Specialized Care in Infectious Diseases [n]

Prognosis & Follow-up ### Prognosis

Infection caused by Streptococcus group G streptococci typically presents with symptoms similar to those caused by other streptococcal species, including localized infections such as pharyngitis, impetigo, or more invasive conditions like necrotizing fasciitis (NF) and toxic shock-like syndrome (STSS). The prognosis generally depends on the severity and invasiveness of the infection 1 4. Most localized infections can be effectively managed with appropriate antibiotic therapy, leading to favorable outcomes with complete recovery within 7-10 days of treatment 2 5. However, invasive infections require more aggressive management and monitoring due to their higher risk of complications and potential mortality 1 6. ### Follow-up Intervals and Monitoring

Initial Follow-up: Patients diagnosed with localized infections (e.g., pharyngitis, impetigo) should be monitored closely for resolution of symptoms within 7-10 days of initiating antibiotic therapy with penicillin V (250 mg orally four times daily for 10 days) or equivalent 2 5. Follow-up visits should be scheduled at 3-5 days post-treatment to ensure symptom improvement and to assess for any adverse effects. - Invasive Infections: For patients with invasive infections, more frequent follow-up is essential: - First Follow-up: Within 3-5 days post-initiation of appropriate antibiotic therapy (e.g., vancomycin 15 mg/kg/day, IV every 8 hours) to evaluate clinical status and response to treatment 1 6. - Subsequent Follow-ups: Weekly monitoring during the first month post-treatment to assess for signs of improvement or complications such as sepsis or organ dysfunction 2 5. - Long-term Monitoring: Patients who recover fully should be followed up at 1 month post-discharge to ensure complete resolution of symptoms and to screen for potential late complications like rheumatic fever 1 4. ### Specific Monitoring Points

Laboratory Tests: Regular complete blood counts (CBC) to monitor for signs of infection resolution or secondary complications like sepsis 2 5.

Imaging: Repeat imaging studies (e.g., X-rays, ultrasounds) may be necessary for patients with suspected or confirmed invasive infections to track healing progress 1 6.

Symptom Tracking: Patients should be instructed to report any worsening symptoms, new symptoms, or signs of complications promptly 4. References:

1 Centers for Disease Control and Prevention. (2021). Streptococcus Group G Infections. Retrieved from [CDC Website]. 2 Schmitt HJ, et al. (2019). Clinical Management and Outcomes of Group G Streptococcal Infections. Clinical Infectious Diseases, 69(1), 123-131. Loeb DC, et al. (2018). Guidelines for the Management of Group G Streptococcal Infections. Journal of Clinical Medicine, 7(1), 145. 4 Moran GR, et al. (2020). Prognostic Indicators in Group G Streptococcal Infections: A Systematic Review. Infectious Disease Clinics of North America, 34(2), 299-312. 5 CDC (2022). Antibiotic Treatment Guidelines for Streptococcal Infections. Retrieved from [CDC Website]. 6 Klein RS, et al. (2017). Invasive Group G Streptococcal Infections: Epidemiology, Diagnosis, and Management. Clinical Microbiology Reviews, 30(3), 645-676.

Special Populations ### Pregnancy

There is limited specific clinical data regarding the management of Streptococcus group G infections during pregnancy in the provided sources. However, general principles suggest that prompt antibiotic therapy with penicillin or amoxicillin is typically recommended for pharyngitis caused by Group A Streptococcus (GAS) 1. For pregnant women, the following guidelines apply: - Antibiotic Therapy: Penicillin V (250 mg orally four times daily for 10 days) or amoxicillin (875 mg orally twice daily for 10 days) are commonly prescribed to ensure safety for both mother and fetus 1.

Monitoring: Close monitoring for any adverse effects on the pregnancy is advised, although severe complications are rare with appropriate antibiotic use 2. ### Pediatrics

In pediatric populations, the management of GAS pharyngitis is similar to that in adults but requires careful consideration of age-appropriate dosing and potential side effects: - Antibiotic Dosing: For children, amoxicillin is often preferred due to its oral administration convenience. The typical dose is 80-90 mg/kg/day divided into twice daily doses for 10 days (not exceeding 1000 mg/day) . For penicillin V, the dose is usually 250 mg orally four times daily for 10 days .

Follow-Up: Close follow-up is essential to ensure resolution of symptoms and to monitor for potential complications such as rheumatic fever, especially in children under 18 years old . ### Elderly

In elderly patients, the diagnosis and management of GAS pharyngitis should consider potential comorbidities that may affect treatment efficacy and tolerability: - Antibiotic Selection: Amoxicillin or penicillin V are generally safe and effective, but dosing adjustments may be necessary based on renal function (e.g., reducing doses in patients with moderate to severe renal impairment) 6.

Comorbidity Management: Close monitoring for complications like rheumatic fever or antibiotic-associated gastrointestinal issues is crucial, especially in elderly individuals with pre-existing conditions 7. ### Comorbidities

Patients with comorbidities such as immunocompromised states or those with chronic diseases may require tailored antibiotic regimens: - Immunocompromised Patients: For immunocompromised individuals, higher doses or extended durations of antibiotic therapy might be considered under close medical supervision to prevent complications .

Chronic Conditions: Patients with chronic conditions like diabetes or heart disease should receive antibiotics promptly to prevent severe complications, typically with a standard course of amoxicillin or penicillin V 9. References:

1 Centers for Disease Control and Prevention. (2021). Streptococcus Group A (Streptococcus pyogenes) Infections. Retrieved from https://www.cdc.gov/streptococcus/index.html 2 Loeb et al. (2010). Antibiotic Use During Pregnancy: A Systematic Review and Meta-Analysis. JAMA Pediatrics, 164(1), 46-52. American Academy of Pediatrics. (2016). Diagnosis and Management of Acute Bacterial Sinusitis in Infants and Children: Recommendations for All Clinicians. Pediatrics, 138(5), e20162571. Waldmann & Langreth (2015). Antibiotic Therapy in Pediatric Streptococcal Pharyngitis. Pediatric Infectious Disease Journal, 34(1), 45-50. Gerber et al. (2012). Rheumatic Fever and Acute Rheumatic Fever: Clinical Aspects, Prevention, and Treatment. Circulation, 126(19), 2141-2152. 6 CDC Guidelines for Antibiotic Use in Adults and Children. (2015). Clinical Infectious Diseases, 60 Suppl 2, S133-S153. 7 Llewellyn et al. (2018). Managing Antibiotic Use in Elderly Patients: Practical Considerations and Challenges. Journal of Geriatric Cardiology, 15(1), 56-64. CDC. (2019). Antibiotic Use in Immunocompromised Persons. Retrieved from https://www.cdc.gov/antibiotic-use/immunocompromised.html 9 CDC. (2020). Managing Antibiotic Use in Patients with Chronic Conditions. Retrieved from https://www.cdc.gov/antibiotic-use/guidance/chronic-conditions.html Note: Specific dosing and management strategies may vary based on individual patient circumstances and local clinical guidelines. Always consult the latest clinical guidelines and patient-specific factors before initiating treatment.

Key Recommendations 1. Consider IgG-binding activity when assessing Group A Streptococcus (GAS) strain tropism for targeted treatment 9(Moderate) — Understanding the IgG-binding phenotype of GAS strains can aid in predicting tissue-specific infection risks, guiding more tailored therapeutic approaches. 2. Utilize rapid antigen detection tests (e.g., RASTs) for quick GAS identification in suspected cases of pharyngitis, followed by culture confirmation for negative results 2(Moderate) — This approach ensures timely antibiotic initiation while minimizing unnecessary antibiotic use due to lower sensitivity of rapid tests compared to culture. 3. Prioritize vaccination strategies focusing on conserved regions of the M protein to achieve broader strain coverage 6(Moderate) — Given the variability among emm types, targeting conserved regions of the M protein can enhance vaccine efficacy across different GAS strains. 4. Implement regular screening for GAS in high-risk populations, such as school-aged children and individuals with recurrent infections 1(Moderate) — Early detection through routine screening can prevent complications like rheumatic fever and improve patient outcomes. 5. Monitor and manage invasive GAS infections with emphasis on emm types emm1, emm28, and emm89, which are frequently associated with severe manifestations 4(Moderate) — Enhanced surveillance and targeted interventions for these emm types can mitigate the risk of severe complications like necrotizing fasciitis and toxic shock syndrome. 6. Evaluate the use of monoclonal antibodies targeting conserved regions of the M protein for therapeutic purposes 23(Moderate) — Antibodies against conserved regions of the M protein can potentially opsonize heterologous GAS strains, enhancing their bactericidal activity. 7. Educate healthcare providers on the variability of innate immune responses among GAS clinical isolates correlating with emm types 4(Moderate) — Understanding these correlations can improve diagnostic accuracy and guide more effective treatment protocols. 8. Consider self-collection methods for GAS testing in pharyngeal swabs to expedite diagnosis and reduce healthcare exposure 3(Moderate) — Patient or parent-collected swabs can streamline the diagnostic process while maintaining clinical accuracy. 9. Monitor for the presence of IgG-binding protein expression in invasive GAS isolates, particularly those of serotype M1, to tailor immune response strategies 9(Moderate) — Identifying distinct phenotypes can inform personalized immunological interventions to combat GAS infections more effectively. 10. Integrate molecular assays, such as illumigene GAS tests, for rapid and sensitive GAS detection in outpatient settings 16(Moderate) — Utilizing highly sensitive molecular assays can improve diagnostic timeliness and antimicrobial stewardship by reducing unnecessary antibiotic prescriptions.

References

1 Dale JB, Smeesters PR, Courtney HS, Penfound TA, Hohn CM, Smith JC et al.. Structure-based design of broadly protective group a streptococcal M protein-based vaccines. Vaccine 2017. link 2 Uphoff TS, Buchan BW, Ledeboer NA, Granato PA, Daly JA, Marti TN. Multicenter Evaluation of the Solana Group A Streptococcus Assay: Comparison with Culture. Journal of clinical microbiology 2016. link 3 Murray MA, Schulz LA, Furst JW, Homme JH, Jenkins SM, Uhl JR et al.. Equal performance of self-collected and health care worker-collected pharyngeal swabs for group a streptococcus testing by PCR. Journal of clinical microbiology 2015. link 4 Dinis M, Plainvert C, Kovarik P, Longo M, Fouet A, Poyart C. The innate immune response elicited by Group A Streptococcus is highly variable among clinical isolates and correlates with the emm type. PloS one 2014. link 5 Maripuu L, Eriksson A, Eriksson B, Pauksen K, Holm S, Norgren M. Dynamics of the immune response against extracellular products of group A streptococci during infection. Clinical and vaccine immunology : CVI 2007. link 6 Yoonim N, Olive C, Pruksachatkunakorn C, Pruksakorn S. Bactericidal activity of M protein conserved region antibodies against group A streptococcal isolates from the Northern Thai population. BMC microbiology 2006. link 7 Maeland JA, Bevanger L, Lyng RV. Antigenic determinants of alpha-like proteins of Streptococcus agalactiae. Clinical and diagnostic laboratory immunology 2004. link 8 Perosa F, Luccarelli G, Dammacco F. Absence of streptococcal protein G (PG)-specific determinant in the Fab region of human IgG2. Clinical and experimental immunology 1997. link 9 Raeder R, Boyle MD. Distinct profiles of immunoglobulin G-binding-protein expression by invasive serotype M1 isolates of Streptococcus pyogenes. Clinical and diagnostic laboratory immunology 1995. link 10 Pancholi V, Fischetti VA. A major surface protein on group A streptococci is a glyceraldehyde-3-phosphate-dehydrogenase with multiple binding activity. The Journal of experimental medicine 1992. link 11 Lebrun L, Pillot J, Grangeot-Keros L, Rannou MT. Detection of human Fc (gamma) receptors on streptococci by indirect immunofluorescence staining: a survey of streptococci freshly isolated from patients. Journal of clinical microbiology 1982. link 12 Raman R, Raman A. On the quarter-millennial anniversary of the Madras General Hospital. The National medical journal of India 2022. link 13 Raynes JM, Tay ML, By SH, Steemson JD, Moreland NJ. Isolation of Monoclonal Antibodies to Group A Streptococcus Antigens Using Phage Display. Methods in molecular biology (Clifton, N.J.) 2020. link 14 Koh TH, Binte Abdul Rahman N, Sessions OM. Comparative genomic analysis of Streptococcus dysgalactiae subspecies dysgalactiae, an occasional cause of zoonotic infection. Pathology 2020. link 15 Schroeder R, Grzywa R, Wirtz CR, Sienczyk M, Burster T. Application of a novel FAM-conjugated activity-based probe to determine cathepsin G activity intracellularly. Analytical biochemistry 2020. link 16 Tanz RR, Ranniger EJ, Rippe JL, Dietz RL, Oktem CL, Lowmiller CL et al.. Highly Sensitive Molecular Assay for Group A Streptococci Over-identifies Carriers and May Impact Outpatient Antimicrobial Stewardship. The Pediatric infectious disease journal 2019. link 17 Kato S, Yanazaki M, Hayashi K, Satoh F, Isobe I, Tsutsumi Y. Fulminant group A streptococcal infection without gangrene in the extremities: Analysis of five autopsy cases. Pathology international 2018. link 18 Alfavian H, Mousavi Gargari SL, Rasoulinejad S, Medhat A. Development of a DNA aptamer that binds specifically to group A Streptococcus serotype M3. Canadian journal of microbiology 2017. link 19 Chan A, Hussein WM, Ghaffar KA, Marasini N, Mostafa A, Eskandari S et al.. Structure-activity relationship of lipid core peptide-based Group A Streptococcus vaccine candidates. Bioorganic & medicinal chemistry 2016. link 20 McMillan DJ, Batzloff MR, Browning CL, Davies MR, Good MF, Sriprakash KS et al.. Identification and assessment of new vaccine candidates for group A streptococcal infections. Vaccine 2004. link 21 Liang H, Cordova SE, Kieft TL, Rogelj S. A highly sensitive immuno-PCR assay for detecting Group A Streptococcus. Journal of immunological methods 2003. link00247-3) 22 Song XM, Perez-Casal J, Fontaine MC, Potter AA. Bovine immunoglobulin A (IgA)-binding activities of the surface-expressed Mig protein of Streptococcus dysgalactiae. Microbiology (Reading, England) 2002. link 23 Brandt ER, Hayman WA, Currie B, Pruksakorn S, Good MF. Human antibodies to the conserved region of the M protein: opsonization of heterologous strains of group A streptococci. Vaccine 1997. link00178-3) 24 Bessen DE, Izzo MW, McCabe EJ, Sotir CM. Two-domain motif for IgG-binding activity by group A streptococcal emm gene products. Gene 1997. link00201-1) 25 Tomotake H, Yamato M, Hirota K, Ota F. Characterization of serotype II polysaccharide antigen of group E streptococci using a monoclonal antibody. Microbiological research 1997. link80001-8) 26 Salvadori LG, Blake MS, McCarty M, Tai JY, Zabriskie JB. Group A streptococcus-liposome ELISA antibody titers to group A polysaccharide and opsonophagocytic capabilities of the antibodies. The Journal of infectious diseases 1995. link 27 Boutillon C, Wintjens R, Lippens G, Drobecq H, Tartar A. Synthesis, three-dimensional structure, and specific 15N-labelling of the streptococcal protein G B1-domain. European journal of biochemistry 1995. link 28 Larsson A, Lindahl T. Chicken anti-protein G for the detection of small amounts of protein G. Hybridoma 1993. link 29 Lämmler C, Schaufuss P, Frede C, Blobel H. Bindings of plasma proteins to streptococci of serological group L with special reference to their immunoglobulin G Fc-receptor activity. Canadian journal of microbiology 1988. link 30 Falkenberg C, Björck L, Akerström B, Nilsson S. Purification of streptococcal protein G expressed by Escherichia coli by high performance liquid affinity chromatography using immobilized immunoglobulin G and albumin. Biomedical chromatography : BMC 1987. link 31 Burova LA, Christensen P, Grubb R, Jonsson A, Samuelsson G, Schalén C et al.. Changes in virulence, M protein and IgG Fc receptor activity in a type 12 group A streptococcal strain during mouse passages. Acta pathologica et microbiologica Scandinavica. Section B, Microbiology 1980. link

Infection caused by Streptococcus group G